ALKS
Alkermes plc NASDAQ Listed Jul 16, 1991$44.99
+1.08%
vs $44.51
Mkt Cap $7.6B
52w Low $26.13
100.0% of range
52w High $44.99
50d MA $37.84
200d MA $32.18
P/E (TTM)
31.5x
EV/EBITDA
19.0x
P/B
4.1x
Debt/Equity
0.0x
ROE
13.3%
P/FCF
15.8x
RSI (14)
65.10
ATR (14)
$1.52
Beta
0.39
50d MA
$37.84
200d MA
$32.18
Avg Volume
2.3M
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Connaught House · Dublin, L2 4 · IE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | BMO | 0.43 | 0.34 | -20.9% | 33.39 | -2.7% | -7.0% | -1.0% | -2.0% | +0.5% | -3.5% | — |
| Oct 28, 2025 | BMO | 0.42 | 0.49 | +16.7% | 29.72 | +1.8% | +4.3% | +1.5% | -2.0% | -0.4% | -1.7% | — |
| Jul 29, 2025 | BMO | 0.41 | 0.52 | +26.8% | 26.15 | +5.2% | +3.3% | +3.4% | -5.2% | +0.2% | +0.3% | — |
| May 1, 2025 | BMO | 0.25 | 0.13 | -48.9% | 28.77 | -0.1% | +6.3% | +3.9% | -1.2% | -3.3% | +0.1% | — |
| Feb 12, 2025 | BMO | 0.81 | 1.04 | +28.4% | 31.96 | +1.3% | +4.8% | +7.5% | -0.3% | +0.0% | -0.2% | — |
| Oct 24, 2024 | BMO | 0.74 | 0.72 | -2.7% | 27.85 | -3.0% | -3.6% | -2.8% | +1.7% | -0.3% | -0.5% | — |
| Jul 24, 2024 | BMO | 0.70 | 0.70 | +0.0% | 25.00 | +7.6% | +6.0% | +5.8% | -0.6% | +0.1% | -1.0% | — |
| May 1, 2024 | BMO | 0.59 | 0.44 | -25.4% | 24.54 | -2.8% | -2.2% | -0.6% | +0.8% | +0.2% | +2.0% | — |
| Feb 15, 2024 | BMO | 0.46 | 0.48 | +4.3% | 27.99 | +2.7% | +16.3% | -1.2% | -5.6% | -4.0% | -0.9% | — |
| Oct 25, 2023 | BMO | 0.44 | 0.64 | +45.5% | 25.32 | -6.9% | -7.4% | +5.3% | -3.2% | +1.7% | -0.5% | — |
| Jul 26, 2023 | BMO | 0.48 | 0.55 | +14.6% | 30.84 | -2.3% | -2.6% | +0.8% | -5.0% | +1.8% | -2.5% | — |
| Apr 26, 2023 | BMO | 0.00 | 0.01 | +172.6% | 30.51 | -2.5% | -7.0% | -0.1% | +0.7% | +0.3% | -0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | BofA Securities | Maintains | Neutral → Neutral | — | $34.77 | $35.00 | +0.7% | +0.4% | -4.5% | +1.2% | +0.4% | -1.9% |
| Mar 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $27.71 | $27.39 | -1.2% | +2.5% | +3.4% | +1.9% | -1.8% | +2.6% |
| Feb 26 | Wells Fargo | Maintains | Overweight → Overweight | — | $31.04 | $31.06 | +0.1% | -1.0% | -2.1% | +0.5% | -3.5% | +0.3% |
| Feb 26 | RBC Capital | Maintains | Outperform → Outperform | — | $31.04 | $31.06 | +0.1% | -1.0% | -2.1% | +0.5% | -3.5% | +0.3% |
| Feb 20 | BofA Securities | Maintains | Neutral → Neutral | — | $32.00 | $31.80 | -0.6% | -0.3% | +0.9% | +3.7% | -7.0% | -1.0% |
| Nov 17 | Truist | Maintains | Buy → Buy | — | $29.04 | $29.36 | +1.1% | +1.0% | -0.2% | -1.9% | -1.7% | +1.5% |
| Nov 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $31.41 | $30.60 | -2.6% | -1.3% | -6.4% | +1.0% | -0.2% | -1.9% |
| Nov 13 | Deutsche Bank | Maintains | Buy → Buy | — | $31.41 | $30.60 | -2.6% | -1.3% | -6.4% | +1.0% | -0.2% | -1.9% |
| Nov 12 | Truist | Maintains | Buy → Buy | — | $33.81 | $27.97 | -17.3% | -7.1% | -1.3% | -6.4% | +1.0% | -0.2% |
| Oct 29 | Wells Fargo | Maintains | Overweight → Overweight | — | $31.00 | $31.00 | +0.0% | +1.5% | -2.0% | -0.4% | -1.7% | +0.7% |
| Oct 29 | Needham | Maintains | Buy → Buy | — | $31.00 | $31.00 | +0.0% | +1.5% | -2.0% | -0.4% | -1.7% | +0.7% |
| Oct 27 | Mizuho | Maintains | Outperform → Outperform | — | $29.80 | $30.05 | +0.8% | -0.3% | +4.3% | +1.5% | -2.0% | -0.4% |
| Oct 23 | RBC Capital | Maintains | Outperform → Outperform | — | $31.09 | $31.22 | +0.4% | -3.4% | -0.8% | -0.3% | +4.3% | +1.5% |
| Oct 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $31.09 | $31.22 | +0.4% | -3.4% | -0.8% | -0.3% | +4.3% | +1.5% |
| Sep 26 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $27.13 | $28.20 | +3.9% | +2.8% | +4.1% | +3.3% | +2.2% | +2.0% |
| Sep 9 | JP Morgan | Maintains | Neutral → Neutral | — | $28.45 | $28.56 | +0.4% | -2.1% | -3.3% | +2.9% | -2.7% | -1.7% |
| Sep 9 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $28.45 | $28.56 | +0.4% | -2.1% | -3.3% | +2.9% | -2.7% | -1.7% |
| Jul 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $27.00 | $27.40 | +1.5% | +3.4% | -5.2% | +0.2% | +0.3% | -0.2% |
| Jul 29 | Needham | Maintains | Buy → Buy | — | $26.15 | $27.50 | +5.2% | +3.3% | +3.4% | -5.2% | +0.2% | +0.3% |
| Jul 21 | Needham | Maintains | Buy → Buy | — | $29.22 | $28.98 | -0.8% | -8.8% | +1.4% | +0.6% | -2.4% | -1.5% |
| Jul 21 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $29.22 | $28.98 | -0.8% | -8.8% | +1.4% | +0.6% | -2.4% | -1.5% |
| Jun 17 | UBS | Upgrade | Neutral → Buy | — | $29.42 | $30.24 | +2.8% | +1.2% | -1.5% | -0.8% | +0.6% | +0.3% |
| May 2 | Baird | Maintains | Outperform → Outperform | — | $30.58 | $31.02 | +1.4% | +3.9% | -1.2% | -3.3% | +0.1% | +0.0% |
| May 2 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $30.58 | $31.02 | +1.4% | +3.9% | -1.2% | -3.3% | +0.1% | +0.0% |
| Apr 28 | UBS | Maintains | Neutral → Neutral | — | $27.84 | $27.93 | +0.3% | +0.3% | +3.1% | +0.0% | +6.3% | +3.9% |
| Mar 27 | Deutsche Bank | Maintains | Buy → Buy | — | $33.69 | $34.41 | +2.1% | -0.5% | -1.0% | -0.6% | -1.5% | +0.4% |
| Mar 4 | UBS | Upgrade | Sell → Neutral | — | $34.11 | $34.68 | +1.7% | +3.8% | -0.3% | -1.8% | -0.9% | +2.6% |
| Feb 14 | Goldman Sachs | Maintains | Buy → Buy | — | $36.00 | $36.06 | +0.2% | -0.3% | +0.0% | -0.2% | -0.9% | -0.5% |
| Feb 13 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $33.50 | $33.62 | +0.4% | +7.5% | -0.3% | +0.0% | -0.2% | -0.9% |
| Nov 13 | Mizuho | Maintains | Outperform → Outperform | — | $29.23 | $29.23 | +0.0% | +0.0% | -3.0% | -0.6% | -2.3% | -0.3% |
| Nov 5 | Stifel | Upgrade | Hold → Buy | — | $26.59 | $27.87 | +4.8% | +6.7% | +3.2% | -1.1% | -0.4% | +4.2% |
| Oct 25 | Goldman Sachs | Maintains | Buy → Buy | — | $26.85 | $26.76 | -0.3% | -2.8% | +1.7% | -0.3% | -0.5% | -2.3% |
| Oct 25 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $26.85 | $26.76 | -0.3% | -2.8% | +1.7% | -0.3% | -0.5% | -2.3% |
| Oct 25 | JP Morgan | Maintains | Neutral → Neutral | — | $26.85 | $26.76 | -0.3% | -2.8% | +1.7% | -0.3% | -0.5% | -2.3% |
| Oct 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $26.85 | $26.76 | -0.3% | -2.8% | +1.7% | -0.3% | -0.5% | -2.3% |
| Oct 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $26.85 | $26.76 | -0.3% | -2.8% | +1.7% | -0.3% | -0.5% | -2.3% |
| Oct 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $28.91 | $28.63 | -1.0% | +0.5% | -3.6% | +0.3% | +0.9% | -0.2% |
| Oct 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $26.59 | $26.42 | -0.6% | +2.9% | +5.6% | +0.5% | -3.6% | +0.3% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $27.66 | $27.78 | +0.4% | +0.6% | -0.3% | +0.3% | +1.9% | +0.7% |
| Jul 25 | Baird | Maintains | Outperform → Outperform | — | $26.51 | $26.68 | +0.6% | +5.8% | -0.6% | +0.1% | -1.0% | -1.1% |
| Jul 25 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $26.51 | $26.68 | +0.6% | +5.8% | -0.6% | +0.1% | -1.0% | -1.1% |
| Jul 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $26.51 | $26.68 | +0.6% | +5.8% | -0.6% | +0.1% | -1.0% | -1.1% |
| Jul 25 | JP Morgan | Maintains | Neutral → Neutral | — | $26.51 | $26.68 | +0.6% | +5.8% | -0.6% | +0.1% | -1.0% | -1.1% |
| Jul 15 | JP Morgan | Maintains | Neutral → Neutral | — | $23.57 | $23.60 | +0.1% | -0.8% | +5.3% | +0.0% | +0.2% | +0.7% |
| Jun 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $24.06 | $24.14 | +0.3% | -1.7% | +2.3% | -0.1% | -1.0% | +1.2% |
| May 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $24.21 | $24.29 | +0.3% | -0.9% | +0.1% | -1.1% | -1.9% | -0.3% |
| May 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $24.01 | $23.87 | -0.6% | -0.6% | +0.8% | +0.2% | +2.0% | -2.0% |
| Apr 19 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $23.76 | $23.65 | -0.5% | +0.4% | +0.9% | +0.8% | +1.6% | -0.9% |
| Apr 9 | Jefferies | Maintains | Buy → Buy | — | $25.93 | $27.29 | +5.2% | +3.1% | -2.2% | -4.4% | -2.3% | -1.6% |
| Apr 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $27.07 | $27.13 | +0.2% | +0.6% | -1.7% | -1.6% | -2.0% | +1.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Gaffin David JosephOff | EVP, CLO, Alkermes, Inc. | Sell | 2,034 | $43.05 | $88K | 229,524 | -1.34% | +2.46% |
| Jun 1, 2026 | Hopkinson Craig C.Off | EVP R&D, Chief Medical Officer | Sell | 9,000 | $41.67 | $375K | 77,389 | -2.25% | -0.82% |
| May 4, 2026 | Gaffin David JosephOff | EVP, CLO, Alkermes, Inc. | Sell | 2,034 | $33.20 | $68K | 231,558 | +6.09% | +1.37% |
| May 1, 2026 | Hopkinson Craig C.Off | EVP R&D, Chief Medical Officer | Sell | 9,000 | $33.40 | $301K | 81,389 | +2.37% | -1.16% |
8-K · 8.01
!! High
Alkermes plc -- 8-K 8.01: Material Event / Announcement
Alkermes referenced a press release in its 8-K filing, but the summary doesn't disclose the specific announcement, limiting assessment of material impact on shareholders.
Jun 15
8-K · 5.02
!!! Very High
Alkermes plc -- 8-K 5.02: Executive Change
May 20
8-K · 8.01
!! High
Alkermes plc -- 8-K 8.01: Material Event / Announcement
Alkermes issued a material press release announcement, though the specific details are referenced as an exhibit rather than disclosed in the filing itself, limiting immediate investor visibility without reviewing the attached document.
May 12
8-K · 2.02
!! High
Alkermes plc -- 8-K 2.02: Earnings Results
Alkermes announced Q1 2026 results and revised full-year 2026 guidance, with updated financial expectations providing investors clarity on the company's performance trajectory and anticipated outcomes.
May 5
8-K
Alkermes Inc. plc -- 8-K Filing
Alkermes plc filed its Q4 2025 financial results, providing investors with year-end performance metrics and guidance for the biopharmaceutical company's future operations.
Feb 25
8-K · 5.02
!!! Very High
Alkermes Inc. plc -- 8-K 5.02: Executive Change
Alkermes appointed Blair C. Jackson as CEO effective July 31, 2026, signaling potential strategic leadership changes that investors should monitor for impact on company direction.
Feb 25
8-K · 2.01
!!! Very High
Alkermes Inc. plc -- 8-K 2.01: Acquisition Completed
Alkermes completed its acquisition of Avadel Pharmaceuticals, expanding its specialty pharma portfolio and potentially enhancing revenue streams through Avadel's existing product lineup and pipeline.
Feb 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Portfolio Management Llc | 9,511,112 | $336M | New | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 7,427,397 | $263M | New | Mar 2026 |
| 3 | Renaissance Technologies Llc | 6,160,428 | $218M | Reduced | Mar 2026 |
| 4 | Jpmorgan Chase & Co | 4,101,789 | $124M | Reduced | Mar 2026 |
| 5 | Morgan Stanley | 3,776,974 | $106M | Added | Dec 2025 |
| 6 | First Trust Advisors Lp | 2,968,785 | $105M | Added | Mar 2026 |
| 7 | Primecap Management Co/ca/ | 2,539,990 | $90M | Reduced | Mar 2026 |
| 8 | Nuveen, Llc | 2,460,569 | $87M | Added | Mar 2026 |
| 9 | Citadel Advisors Llc | 2,241,584 | $79M | Added | Mar 2026 |
| 10 | Soleus Capital Management, L.p. | 1,970,864 | $70M | Added | Mar 2026 |
| 11 | Northern Trust Corp | 1,697,082 | $60M | Added | Mar 2026 |
| 12 | Rtw Investments, Lp | 1,672,356 | $59M | — | Mar 2026 |
| 13 | Fmr Llc | 1,323,747 | $47M | Reduced | Mar 2026 |
| 14 | Bank Of America Corp /de/ | 1,210,851 | $43M | Added | Mar 2026 |
| 15 | Avoro Capital Advisors Llc | 1,200,000 | $42M | Reduced | Mar 2026 |
| 16 | Pictet Asset Management Holding Sa | 1,477,214 | $41M | Added | Dec 2025 |
| 17 | Artisan Partners Limited Partnership | 1,111,741 | $39M | Reduced | Mar 2026 |
| 18 | Bank Of New York Mellon Corp | 1,036,460 | $37M | Reduced | Mar 2026 |
| 19 | Marshall Wace, Llp | 999,322 | $35M | Added | Mar 2026 |
| 20 | Panagora Asset Management Inc | 932,942 | $33M | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$7.59B
Enterprise Value
$6.27B
P/E (TTM)
31.46x
Forward P/E
—
PEG Ratio
-0.56x
P/B
4.07x
P/S
5.14x
P/FCF
15.81x
EV/EBITDA
18.96x
Shares Out
168.7M
Financials (TTM)
Revenue
$1.48B
Net Income
$241.7M
EBITDA
$330.9M
Free Cash Flow
$480.3M
Op Cash Flow
$520.8M
EPS Basic
$1.47
EPS Diluted
$1.43
EPS Forward
$-0.48
Gross Margin
86.3%
Op Margin
17.2%
Net Margin
16.4%
Balance Sheet
Total Assets
$2.53B
Total Liab.
$711.0M
Total Equity
$1.82B
Cash
$1.32B
LT Debt
$0
Book Value/Sh
$11.05
Debt/Equity
0.04x
Current Ratio
3.55
Quick Ratio
3.19
Returns & Growth
ROE
13.3%
ROA
9.7%
ROIC
10.6%
Rev Growth YoY
-5.2%
EPS Growth YoY
-33.8%
Price Returns
2W
+10.0%
1M
+25.2%
3M
+40.2%
6M
+42.6%
12M
+37.8%
Technicals
52W High
$44.99
52W Low
$26.13
50d MA
$37.84
200d MA
$32.18
RSI (14)
65.10
ATR (14)
$1.52
Beta
0.39
Avg Volume
2.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$44.00
High
$45.00
Low
$43.00
Median
$44.00
Data updated apr 24, 2026 5:19pm
· Source: financialmodelingprep.com